series-a
Stage
2
Investors
About
T-CURX is a German biotechnology company developing non-viral CAR-T cell therapies by delivering Sleeping Beauty transposon vectors to T cells via T cell-targeted lipid nanoparticles to enable stable CAR expression in vivo or bedside-manufactured CAR-T. The company is advancing clinical CAR-T programs targeting indications including AML and CLL as well as targets expressed in both hematological malignancies and solid tumors.
Explore T-CURX's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.